Company Overview of Palatin Technologies Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has completed Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD). Its drug development programs include Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Next Generation Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; and PL-3994, a natriuretic peptide receptor-A agonist that has completed Phase I clinical trial for t...
4B Cedar Brook Drive
Cranbury, NJ 08512
Founded in 1986
Key Executives for Palatin Technologies Inc.
Total Annual Compensation: $450.0K
Chief Financial Officer
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.
Palatin Technologies Inc. Key Developments
Palatin Technologies, Inc. Initiates Phase 3 Reconnect Study in United States for Female Sexual Dysfunction
Dec 29 14
Palatin Technologies Inc. announced that it has started its bremelanotide pivotal registration program. The company has initiated its phase 3 reconnect study in the United States for the treatment of female sexual dysfunction (FSD). The start of the reconnect study phase 3 clinical trial in the U.S triggers a development milestone payment of $3 million from Gedeon Richter Plc, Palatin's partner in Europe for bremelanotide for FSD. Palatin is also eligible to receive regulatory and sales milestones, and low double-digit royalties on net sales in the European licensed territory. Protocol 301 of the reconnect study is a multicenter (~80 sites), randomized, placebo controlled, parallel-group, eight month trial with an open-label extension phase. It is designed to randomize approximately 550 women in North America to evaluate the efficacy and safety of subcutaneous bremelanotide in premenopausal women with hypoactive sexual desire disorder (HSDD) as an on-demand, as-needed treatment. Initial data from the study is anticipated in the middle of calendar year 2016.
Palatin Technologies Inc. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended September 30, 2014
Nov 18 14
Palatin Technologies Inc. reported consolidated unaudited earnings results for the first quarter ended September 30, 2014. For the period, the company reported license revenue was $4,932,315. Income from operations was $893,888 compared with $4,492,650 for the same period last year. Net income was $794,674 or $0.01 diluted per share compared with net loss of $4,489,182 or $0.01 diluted per share for the same period last year. The increase in net income last fiscal year was mainly attributable to the recognition of $4.9 million in revenue pursuant to its agreement with Gedeon Richter.
Palatin Technologies Inc. to Report Q1, 2015 Results on Nov 18, 2014
Nov 13 14
Palatin Technologies Inc. announced that they will report Q1, 2015 results at 11:00 AM, US Eastern Standard Time on Nov 18, 2014
Similar Private Companies By Industry
Recent Private Companies Transactions
December 24, 2014